Ca2+ sensitizers: An emerging class of agents for counterbalancing weakness in skeletal muscle diseases?

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Ca2+ sensitizers : An emerging class of agents for counterbalancing weakness in skeletal muscle diseases? / Ochala, Julien.

I: Neuromuscular Disorders, Bind 20, Nr. 2, 02.2010, s. 98-101.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Ochala, J 2010, 'Ca2+ sensitizers: An emerging class of agents for counterbalancing weakness in skeletal muscle diseases?', Neuromuscular Disorders, bind 20, nr. 2, s. 98-101. https://doi.org/10.1016/j.nmd.2009.11.010

APA

Ochala, J. (2010). Ca2+ sensitizers: An emerging class of agents for counterbalancing weakness in skeletal muscle diseases? Neuromuscular Disorders, 20(2), 98-101. https://doi.org/10.1016/j.nmd.2009.11.010

Vancouver

Ochala J. Ca2+ sensitizers: An emerging class of agents for counterbalancing weakness in skeletal muscle diseases? Neuromuscular Disorders. 2010 feb.;20(2):98-101. https://doi.org/10.1016/j.nmd.2009.11.010

Author

Ochala, Julien. / Ca2+ sensitizers : An emerging class of agents for counterbalancing weakness in skeletal muscle diseases?. I: Neuromuscular Disorders. 2010 ; Bind 20, Nr. 2. s. 98-101.

Bibtex

@article{47564c50962241e98b709a7c5fab2bfd,
title = "Ca2+ sensitizers: An emerging class of agents for counterbalancing weakness in skeletal muscle diseases?",
abstract = "Ca2+ ions are key regulators of skeletal muscle contraction. By binding to contractile proteins, they initiate a cascade of molecular events leading to cross-bridge formation and ultimately, muscle shortening and force production. The ability of contractile proteins to respond to Ca2+ attachment, also known as Ca2+ sensitivity, is often compromised in acquired and congenital skeletal muscle disorders. It constitutes, undoubtedly, a major physiological cause of weakness for patients. In this review, we discuss recent studies giving strong molecular and cellular evidence that pharmacological modulators of some of the contractile proteins, also termed Ca2+ sensitizers, are efficient agents to improve Ca2+ sensitivity and function in diseased skeletal muscle cells. In fact, they compensate for the impaired contractile proteins response to Ca2+ binding. Currently, such Ca2+ sensitizing compounds are successfully used for reducing problems in cardiac disorders. Therefore, in the future, under certain conditions, these agents may represent an emerging class of agents to enhance the quality of life of patients suffering from skeletal muscle weakness.",
keywords = "Ca sensitizing agents, Myopathies, Skeletal muscle, Weakness",
author = "Julien Ochala",
year = "2010",
month = feb,
doi = "10.1016/j.nmd.2009.11.010",
language = "English",
volume = "20",
pages = "98--101",
journal = "Journal of Neuromuscular Diseases",
issn = "0960-8966",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Ca2+ sensitizers

T2 - An emerging class of agents for counterbalancing weakness in skeletal muscle diseases?

AU - Ochala, Julien

PY - 2010/2

Y1 - 2010/2

N2 - Ca2+ ions are key regulators of skeletal muscle contraction. By binding to contractile proteins, they initiate a cascade of molecular events leading to cross-bridge formation and ultimately, muscle shortening and force production. The ability of contractile proteins to respond to Ca2+ attachment, also known as Ca2+ sensitivity, is often compromised in acquired and congenital skeletal muscle disorders. It constitutes, undoubtedly, a major physiological cause of weakness for patients. In this review, we discuss recent studies giving strong molecular and cellular evidence that pharmacological modulators of some of the contractile proteins, also termed Ca2+ sensitizers, are efficient agents to improve Ca2+ sensitivity and function in diseased skeletal muscle cells. In fact, they compensate for the impaired contractile proteins response to Ca2+ binding. Currently, such Ca2+ sensitizing compounds are successfully used for reducing problems in cardiac disorders. Therefore, in the future, under certain conditions, these agents may represent an emerging class of agents to enhance the quality of life of patients suffering from skeletal muscle weakness.

AB - Ca2+ ions are key regulators of skeletal muscle contraction. By binding to contractile proteins, they initiate a cascade of molecular events leading to cross-bridge formation and ultimately, muscle shortening and force production. The ability of contractile proteins to respond to Ca2+ attachment, also known as Ca2+ sensitivity, is often compromised in acquired and congenital skeletal muscle disorders. It constitutes, undoubtedly, a major physiological cause of weakness for patients. In this review, we discuss recent studies giving strong molecular and cellular evidence that pharmacological modulators of some of the contractile proteins, also termed Ca2+ sensitizers, are efficient agents to improve Ca2+ sensitivity and function in diseased skeletal muscle cells. In fact, they compensate for the impaired contractile proteins response to Ca2+ binding. Currently, such Ca2+ sensitizing compounds are successfully used for reducing problems in cardiac disorders. Therefore, in the future, under certain conditions, these agents may represent an emerging class of agents to enhance the quality of life of patients suffering from skeletal muscle weakness.

KW - Ca sensitizing agents

KW - Myopathies

KW - Skeletal muscle

KW - Weakness

UR - http://www.scopus.com/inward/record.url?scp=75149126663&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2009.11.010

DO - 10.1016/j.nmd.2009.11.010

M3 - Review

C2 - 20006502

AN - SCOPUS:75149126663

VL - 20

SP - 98

EP - 101

JO - Journal of Neuromuscular Diseases

JF - Journal of Neuromuscular Diseases

SN - 0960-8966

IS - 2

ER -

ID: 245665024